Vriesendorp H M, Klapwijk W M, Visser T P, Zurcher C, van Bekkum D W
Immunogenetics. 1982 Jan;15(1):79-94. doi: 10.1007/BF00375505.
Graft-versus-host disease (GvHD) after bone-marrow transplantation in dogs is controlled by many different genetic systems. In littermate combinations identical for the major histocompatibility complex (MHC) the number of systems that influence GvHD is related to the number of donor lymphocytes injected. If the number of donor lymphocytes administered is sufficiently low, minor histocompatibility systems do not influence survival after bone-marrow transplantation. With increasing numbers of donor lymphocytes the beneficial influence of MHC matching on GvH incidence and severity disappears and minor histocompatibility antigens, coded for on at least two other autosomal chromosomes as well as possibly the Y chromosome, can cause severe GvHD. In contrast, the X chromosome does not appear to carry a histocompatibility system that is of relevance to GvHD control. The severity and tissue distribution of histological signs of GvHD in recipients of bone-marrow and lymph-node cells from MHC-identical donors are similar to those in recipients of MHC-mismatched bone-marrow cells. Female donors do appear to cause severe GvHD more frequently than males. In contrast to rhesus monkey and human bone-marrow cells, dog bone-marrow cells are negative in PHA tests. This is in accordance with the generally benign course of GvHD in dogs that are treated with bone-marrow cells only from histocompatible littermate donors. The influence of the sex of the bone-marrow donor on GvHD incidence and severity is not reflected in differences between PHA tests with male and female dog lymphocytes. A better predictive test for GvH potential than the PHA test appears to be needed. Alternatives to additional donor selection for the prevention of GvHD in histocompatible recipients appear to be the use of a male donor and the removal of lymphocytes from bone-marrow-cell suspensions prior to transplantation.
犬骨髓移植后的移植物抗宿主病（GvHD）受多种不同遗传系统的控制。在主要组织相容性复合体（MHC）相同的同窝仔犬组合中，影响GvHD的系统数量与注入的供体淋巴细胞数量有关。如果给予的供体淋巴细胞数量足够少，次要组织相容性系统不会影响骨髓移植后的存活情况。随着供体淋巴细胞数量的增加，MHC匹配对移植物抗宿主病发生率和严重程度的有益影响消失，至少在另外两条常染色体以及可能的Y染色体上编码的次要组织相容性抗原可导致严重的GvHD。相比之下，X染色体似乎不携带与GvHD控制相关的组织相容性系统。来自MHC相同供体的骨髓和淋巴结细胞受体中GvHD组织学体征的严重程度和组织分布与MHC不匹配的骨髓细胞受体中的相似。雌性供体似乎比雄性供体更频繁地导致严重的GvHD。与恒河猴和人类骨髓细胞不同，犬骨髓细胞在PHA试验中呈阴性。这与仅用来自组织相容性同窝仔犬供体的骨髓细胞治疗的犬中GvHD的一般良性病程一致。骨髓供体性别对GvHD发生率和严重程度的影响并未体现在用雄性和雌性犬淋巴细胞进行的PHA试验之间的差异中。似乎需要一种比PHA试验更好的预测移植物抗宿主病潜力的检测方法。对于在组织相容性受体中预防GvHD，除了额外选择供体外，其他替代方法似乎是使用雄性供体以及在移植前从骨髓细胞悬液中去除淋巴细胞。
